Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tulppala, M.
Right arrow Articles by Ylikorkala, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tulppala, M.
Right arrow Articles by Ylikorkala, O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol 12, 1567-1572, Copyright © 1997 by Oxford University Press


ARTICLES

Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production

M Tulppala, M Marttunen, V Soderstrom-Anttila, T Foudila, K Ailus, T Palosuo and O Ylikorkala
Department of Obstetrics and Gynaecology, University Central Hospital of Helsinki, Finland.

Early pregnancies in women with a history of recurrent spontaneous abortion (RSA) are accompanied by a deficiency in vasodilatory and anti- aggregatory prostacyclin (PGI2) and/or overproduction of its endogenous antagonist thromboxane A2 (TXA2). We evaluated the effect of a low-dose aspirin (LDA) on PGI2 and TXA2 production and on pregnancy outcome in RSA women with and without detectable anticardiolipin antibodies (ACA). Of 82 RSA women studied, 66 became pregnant, and of them, 33 (six with elevated and 27 with normal ACA concentrations) were randomized to receive LDA (50 mg/day) and 33 (six with elevated and 27 with normal ACA concentrations) to receive placebo (PLA) from a mean of 6.6 days after the missed period to delivery. Treatment with LDA inhibited platelet TXA2 production similarly in RSA women with and without detectable ACA and with continuing pregnancies (7.0 +/- 0.7 ng/ml, LDA group versus 254.5 +/- 37.8 ng/ml, PLA group, mean +/- SEM, P < 0.0001) or miscarrying pregnancies (13.8 +/- 3.8 ng/ml compared with 233.6 +/- 59.8 ng/ml, P < 0.0001 respectively). Furthermore, LDA decreased urinary excretion of the TXA2 metabolite (2,3-dinor-TXB2) both in pregnancies which went to term (6.1 +/- 0.6 ng/mmol creatinine, LDA group versus 19.3 +/- 3.0 ng/mmol creatinine, PLA group, P < 0.0001) or again ended in miscarriage (4.7 +/- 0.8 ng/mmol creatinine versus 17.3 +/- 4.4 ng/mmol creatinine, P < 0.0001 respectively), but did not affect the excretion of the prostacyclin metabolite (2,3-dinor-6-keto- PGF1alpha). Early pregnancy ultrasound examination revealed a living fetus in 58 women. Of these, seven in the LDA group (23.3%, four with elevated and three with normal ACA concentrations) and five in the PLA group (17.9%, two with elevated and three with normal ACA concentrations; not significant) experienced a miscarriage. All infants were healthy, and the frequency of growth retardation was similar in both groups (13.0%). One woman in the LDA group (4.3%) and three women receiving PLA (13.0%) developed pre-eclampsia (not significant). Therefore, although treatment with LDA caused a desirable biochemical effect, it did not improve pregnancy outcome in RSA women with or without detectable ACA.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 844S - 886S.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
T.A. Gelbaya, M. Kyrgiou, T.C. Li, C. Stern, and L.G. Nardo
Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis
Hum. Reprod. Update, July 1, 2007; 13(4): 357 - 364.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
N. Di Simone, P.L. Meroni, M. D'Asta, F. Di Nicuolo, M.C. D'Alessio, and A. Caruso
Pathogenic role of anti-{beta}2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin
Hum. Reprod. Update, March 1, 2007; 13(2): 189 - 196.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
W. Lim, M. A. Crowther, and J. W. Eikelboom
Management of Antiphospholipid Antibody Syndrome: A Systematic Review
JAMA, March 1, 2006; 295(9): 1050 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Pakkila, J. Rasanen, S. Heinonen, H. Tinkanen, L. Tuomivaara, K. Makikallio, M. Hippelainen, J.S. Tapanainen, and H. Martikainen
Low-dose aspirin does not improve ovarian responsiveness or pregnancy rate in IVF and ICSI patients: a randomized, placebo-controlled double-blind study
Hum. Reprod., August 1, 2005; 20(8): 2211 - 2214.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
H Carp
Cytokines in recurrent miscarriage
Lupus, September 1, 2004; 13(9): 630 - 634.
[Abstract] [PDF]


Home page
Hum ReprodHome page
O. Ozturk, M. Greaves, and A. Templeton
Aspirin Dilemma: Remodelling the hypothesis from a fertility perspective
Hum. Reprod., May 1, 2002; 17(5): 1146 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Rai, M. Backos, N. Baxter, I. Chilcott, and L. Regan
Recurrent miscarriage--an aspirin a day?
Hum. Reprod., October 1, 2000; 15(10): 2220 - 2223.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A.B.C. Coumans, P.C. Huijgens, C. Jakobs, R. Schats, J.I.P. de Vries, M.G. van Pampus, and G.A. Dekker
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion
Hum. Reprod., January 1, 1999; 14(1): 211 - 214.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.